Compare TMDX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMDX | CNS |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 4.4B |
| IPO Year | 2019 | 2004 |
| Metric | TMDX | CNS |
|---|---|---|
| Price | $72.00 | $71.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 3 |
| Target Price | ★ $98.73 | $72.33 |
| AVG Volume (30 Days) | ★ 713.8K | 291.7K |
| Earning Date | 11-02-2026 | 10-15-2026 |
| Dividend Yield | N/A | ★ 3.81% |
| EPS Growth | ★ 382.18 | N/A |
| EPS | 0.61 | ★ 1.77 |
| Revenue | ★ $605,494,000.00 | $427,536,000.00 |
| Revenue This Year | $22.57 | $10.15 |
| Revenue Next Year | $17.85 | $5.52 |
| P/E Ratio | $119.75 | ★ $39.76 |
| Revenue Growth | ★ 37.13 | 4.07 |
| 52 Week Low | $60.11 | $58.39 |
| 52 Week High | $156.00 | $86.56 |
| Indicator | TMDX | CNS |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 48.67 |
| Support Level | $66.64 | $69.15 |
| Resistance Level | $79.60 | $74.01 |
| Average True Range (ATR) | 3.93 | 2.52 |
| MACD | -0.62 | 0.41 |
| Stochastic Oscillator | 26.43 | 71.91 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.